Fortis Healthcare Ltd
FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. [1]
Company controls its diagnostics business through its 57% owned subsidiary SRL Limited. It is amongst the largest private diagnostics chains. It has a presence in over 600 cities and towns, with an established strength of 415 laboratories, 8,200 direct clients and 1,400 Collection Centers. [2]
- Market Cap ₹ 67,327 Cr.
- Current Price ₹ 892
- High / Low ₹ 1,105 / 767
- Stock P/E 337
- Book Value ₹ 122
- Dividend Yield 0.11 %
- ROCE 3.96 %
- ROE 2.13 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 51.4% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 63.0%
Cons
- Stock is trading at 7.35 times its book value
- Company has a low return on equity of 1.64% over last 3 years.
- Earnings include an other income of Rs.172 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Hospital
Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 611 | 612 | 645 | 659 | 656 | 702 | 633 | 863 | 1,053 | 1,181 | 1,446 | 1,792 | 1,849 | |
| 758 | 737 | 792 | 697 | 780 | 633 | 605 | 747 | 919 | 988 | 1,190 | 1,395 | 1,436 | |
| Operating Profit | -148 | -125 | -146 | -38 | -123 | 69 | 28 | 116 | 134 | 193 | 256 | 397 | 413 |
| OPM % | -24% | -20% | -23% | -6% | -19% | 10% | 4.4% | 13% | 13% | 16% | 18% | 22% | 22% |
| 220 | 166 | 165 | 70 | 522 | 809 | 248 | 118 | 197 | 236 | 83 | 196 | 172 | |
| Interest | 81 | 65 | 106 | 64 | 192 | 160 | 141 | 130 | 106 | 82 | 112 | 206 | 201 |
| Depreciation | 27 | 25 | 27 | 29 | 27 | 97 | 111 | 113 | 116 | 101 | 113 | 118 | 118 |
| Profit before tax | -36 | -50 | -114 | -60 | 180 | 621 | 24 | -9 | 109 | 247 | 114 | 270 | 266 |
| Tax % | -5% | -19% | -34% | 6% | 31% | 17% | 83% | 48% | 12% | 19% | 44% | 15% | |
| -34 | -40 | -75 | -64 | 123 | 513 | 4 | -13 | 96 | 199 | 64 | 230 | 226 | |
| EPS in Rs | -0.73 | -0.87 | -1.44 | -1.23 | 1.63 | 6.80 | 0.06 | -0.18 | 1.27 | 2.64 | 0.84 | 3.05 | 3.00 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 78% | 38% | 118% | 33% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 23% |
| 3 Years: | 19% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 51% |
| 3 Years: | 53% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 27% |
| 3 Years: | 40% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 1% |
| 3 Years: | 2% |
| Last Year: | 2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 3,217 | 3,284 | 3,754 | 3,708 | 7,608 | 8,122 | 8,127 | 8,114 | 8,209 | 8,332 | 8,319 | 8,474 |
| 1,234 | 1,076 | 647 | 555 | 1,478 | 1,361 | 1,380 | 1,193 | 785 | 659 | 2,039 | 2,078 | |
| 246 | 215 | 242 | 234 | 279 | 343 | 320 | 365 | 620 | 640 | 887 | 688 | |
| Total Liabilities | 5,159 | 5,039 | 5,161 | 5,016 | 10,120 | 10,581 | 10,582 | 10,426 | 10,369 | 10,387 | 11,999 | 11,994 |
| 190 | 172 | 186 | 203 | 180 | 906 | 853 | 770 | 492 | 467 | 925 | 1,266 | |
| CWIP | 169 | 182 | 199 | 166 | 165 | 33 | 7 | 6 | 3 | 260 | 42 | 95 |
| Investments | 2,411 | 2,428 | 3,603 | 3,658 | 8,310 | 8,153 | 8,898 | 8,845 | 8,848 | 8,834 | 10,178 | 10,071 |
| 2,389 | 2,257 | 1,174 | 989 | 1,466 | 1,489 | 824 | 804 | 1,027 | 825 | 853 | 562 | |
| Total Assets | 5,159 | 5,039 | 5,161 | 5,016 | 10,120 | 10,581 | 10,582 | 10,426 | 10,369 | 10,387 | 11,999 | 11,994 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -144 | -761 | 22 | -15 | -61 | 100 | 32 | 76 | 198 | 218 | 334 | 116 | |
| 294 | 394 | -72 | 245 | -4,688 | 810 | 28 | 238 | 205 | 44 | -1,572 | 11 | |
| -170 | 370 | 45 | -292 | 4,792 | -972 | 6 | -320 | -395 | -245 | 1,276 | -176 | |
| Net Cash Flow | -20 | 3 | -5 | -62 | 43 | -62 | 66 | -6 | 8 | 18 | 38 | -49 |
| Free Cash Flow | -212 | -761 | -35 | -60 | -66 | 86 | -23 | 50 | 145 | 44 | -31 | -190 |
| CFO/OP | 77% | 594% | 13% | 46% | 8% | 161% | 148% | 108% | 173% | 125% | 130% | 56% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57 | 61 | 43 | 39 | 47 | 42 | 37 | 32 | 34 | 41 | 46 | 49 |
| Inventory Days | 18 | 15 | 14 | 19 | 17 | 25 | 21 | 25 | 18 | 15 | 16 | 18 |
| Days Payable | 240 | 289 | 340 | 392 | 542 | 525 | 520 | 494 | 572 | 608 | 643 | 399 |
| Cash Conversion Cycle | -165 | -213 | -284 | -334 | -479 | -457 | -462 | -438 | -520 | -553 | -581 | -332 |
| Working Capital Days | 354 | -168 | -206 | -130 | -594 | -59 | -52 | -25 | -24 | -74 | -165 | -139 |
| ROCE % | 0% | 1% | -0% | 1% | 5% | 9% | 1% | 1% | 2% | 2% | 3% | 4% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Diagnostic Tests Volume (Agilus) Mn tests |
|
||||
| International Patient Revenue Share (Hospital Business) % |
|||||
| ALOS (Average Length of Stay) Days |
|||||
| ARPOB (Average Revenue Per Occupied Bed) INR Cr p.a. |
|||||
| Customer Touchpoints (CTPs) - Agilus Diagnostics Count |
|||||
| Healthcare Facilities (Hospitals) Count |
|||||
| Hospital Occupancy % |
|||||
| Operational Beds (Hospitals, incl. O&M) Beds |
|||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Fortis signed 29-year agreements for a 400+ bed Delhi hospital and a ₹567 crore loan.
-
Intimation For Signing The Definitive Agreements By Fortis Hospotel Limited (Wholly Owned Subsidiary Of The Company) To Provide Healthcare Services To A 400+ Bedded Super Specialty Hospital In Ashok Vihar, New Delhi
- Fortis subsidiary signs 29-year healthcare agreement for 400+ bed Ashok Vihar hospital; loan up to Rs 567 crore.
-
Announcement Under Regulation 30 Of SEBI (LODR), Regulations, 2015 About Filing Of Special Leave Petition ('SLP') Before The Hon'Ble Supreme Court Of India
- Fortis filed an SLP on September 16, 2026 against Delhi High Court order in Daiichi Sankyo case.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Fortis schedules investor meets on 21-22 September 2026 in Mumbai with BNP Paribas and J.P. Morgan.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from nse
-
Annual Report 2013
from bse
Concalls
-
Sep 2026TranscriptPPTREC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT REC
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025TranscriptPPT
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
May 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
May 2023Transcript PPT
-
May 2023TranscriptAI SummaryPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Aug 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Jun 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Jun 2019TranscriptPPT
-
Feb 2019TranscriptAI SummaryPPT
-
Jul 2018TranscriptPPT
-
Jun 2018TranscriptAI SummaryPPT
-
Mar 2018TranscriptAI SummaryPPT
-
Aug 2017TranscriptAI SummaryPPT
-
May 2017TranscriptAI SummaryPPT
-
Feb 2017TranscriptAI SummaryPPT
-
Aug 2016TranscriptAI SummaryPPT
-
May 2016TranscriptAI SummaryPPT
-
Feb 2016TranscriptAI SummaryPPT
Business Segments:[1]
a) Hospital Segment:
Co. operates multi-specialty and super-specialty hospitals providing inpatient and outpatient treatments across various disciplines.
-Network:[2]
The company has a highly accredited health
care network in India with 8100+ doctors, 9500+ nurses, and 28,500+ employees.
It operates 36 hospitals, including joint
ventures and O&M centers, with 5,800 operational beds. The network includes
4 JCI-accredited and 34 NABH-accredited facilities.